optimization stages along with characterization assays for large molecules , vaccines and drug products .
Analytical characterization focuses on physico-chemical and structural characterization of new biological entities ( NBEs ), biosimilars and vaccines . Equipped with cutting-edge technologies and state-of-the-art facilities , a power-packed analytical data right from primary structure analyses to higher-order structure of biotherapeutics form the core .
The Clinical Bioanalysis Lab uses immunoanalytical techniques such as ELISA , LC-MS and Electrochemiluminescence ( ECLA ) which are critical for the analysis of large protein molecules and antibody drugs , including biosimilars . In addition , it also offers state-of-the-art technologies such as Flow Cytometry , qPCR and ELISpot assays in a highly regulated environment to support clinical studies .
How do you see the current trends in biopharma shaping the industry ' s future ? What strategies do you employ to ensure the company remains competitive in the rapidly evolving industry ?
The key drivers of the growth include the rising investment in pharmaceutical research and development ( R & D ), the number of clinical trials , drugs , and biologics market despite the COVID-19 pandemic , demand for specialized testing services among end users , and the need for novel clinical trial designs for complex cell and gene therapies . The high cost of in-house drug development has also resulted in biopharma companies increasingly choosing to outsource the research work to CROs .
Since the Agreement on Trade-Related Aspects of Intellectual Property Rights , or TRIPS , a globally recognized intellectual property pact , the drug industry ’ s interest in India for cheap access to highly qualified scientists and the potential for selling patented drugs in India has significantly increased . Now , India ’ s top CROs and CDMOs are asserting themselves on the global stage . They are courting biotechnology companies by setting up satellite labs in the US and Europe , hiring managers with bioharma or chemical experience to initiate and drive processes . Their goal is to compete the global CROs while becoming less of an assistant and more of a partner for their drug industry clients .
We understand that to become a successful CROs we have to keep up with globally recognized processes , quality standards , and operating models to compete in the world market , taking into considerations that , state-of-the-art facilities and topnotch teams may not compatible with offering low-cost services . Even then , large pharmaceutical companies turn to India to fill a gap between the type of R & D that they need and the number
BioTech
BIOVOICENEWS . COM 53